Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191776 | 0.89 | HTR2A (0.66) | LTA4HHTR2AOPRM1 | |
| SCHEMBL5174985 | 0.88 | LTA4H (0.76) | LTA4HHTR2AKCNH2 | |
| SCHEMBL5175617 | 0.86 | LTA4H (0.77) | LTA4HNPC1RAB9AHTR2AKCNH2 | |
| SCHEMBL5175237 | 0.86 | LTA4H (0.56) | LTA4HNPC1RAB9AHTR2AOPRM1 | |
| SCHEMBL6681568 | 0.84 | LTA4H (0.71) | LTA4HNPC1RAB9AKCNH2 | |
| SCHEMBL5175844 | 0.84 | LTA4H (0.54) | LTA4HNPC1RAB9AHTR2AOPRM1 | |
| SCHEMBL27735063 | 0.83 | LTA4H (0.57) | LTA4HNPC1RAB9AHTR2AKCNH2 | |
| SCHEMBL17842304 | 0.83 | NPC1 (0.70) | LTA4HNPC1RAB9AKCNH2 | |
| SCHEMBL5174903 | 0.82 | LTA4H (0.74) | LTA4HHTR2AKCNH2 | |
| SCHEMBL5173600 | 0.82 | LTA4H (0.81) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | LTA4H 1/4885NPC1 1667/4885RAB9A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.